Arrowhead Pharmaceuticals, Inc.
ARWR
$15.93
$0.130.82%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -143.97M | -639.71M | -599.49M | -538.64M | -470.79M |
| Total Depreciation and Amortization | 21.13M | 19.57M | 18.60M | 17.43M | 15.92M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 113.31M | 100.34M | 92.96M | 93.73M | 90.76M |
| Change in Net Operating Assets | 70.68M | 28.52M | 25.09M | 75.91M | 107.18M |
| Cash from Operations | 61.15M | -491.28M | -462.85M | -351.56M | -256.92M |
| Capital Expenditure | -51.55M | -80.33M | -141.47M | -181.09M | -213.24M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -507.73M | -327.67M | -278.60M | 14.45M | 29.75M |
| Cash from Investing | -559.28M | -408.00M | -420.07M | -166.64M | -183.49M |
| Total Debt Issued | 392.00M | 392.00M | 392.00M | -- | -- |
| Total Debt Repaid | -151.63M | -- | -- | -- | -- |
| Issuance of Common Stock | 245.25M | 432.02M | 431.65M | 432.25M | 433.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 66.87M | 66.87M | 46.87M | 50.00M | 0.00 |
| Cash from Financing | 552.49M | 890.89M | 870.52M | 482.25M | 433.00M |
| Foreign Exchange rate Adjustments | 3.64M | 4.07M | 4.20M | 14.00K | 158.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.01M | -4.33M | -8.21M | -35.94M | -7.26M |